Mitochondrial Replacement Slippery Slope? | GenomeWeb

The UK government's recent decision to move toward enabling human trials in which mitochondrial replacement from donor DNA would be used to treat mitochondrial disease in embryos has stirred up a predictable ethical debate. Does this step effectively green-light human germline modification, a step possibly towards even more profound human genetic engineering?

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.